News

Zipalertinib plus platinum-based chemotherapy significantly improved progression-free survival at a planned interim analysis of the phase 3 REZILIENT3 trial.

Registry data show bulky lymphoma drives different treatment choices and mixed survival effects, highlighting the need to standardize tumor bulk definitions.

During a live event, Eric K. Singhi, MD, and participants discussed how CNS activity and cumulative toxicity, not guideline listing alone, are shaping frontline treatment selection in ROS1-positive advanced NSCLC.

The FDA has granted breakthrough device designation to Freenome's SimpleScreen Lung, an investigational blood-based test for high-risk lung cancer screening.

Three-year follow-up from the single-arm trial that led to talquetamab's approval showed durable progression-free survival and overall survival in heavily pretreated multiple myeloma.

Experts weigh response speed, survival and quality of life to choose first-line IO-TKI or dual immunotherapy for metastatic clear cell RCC.

The analysis builds on results from the phase 3 KEYNOTE-689 trial of perioperative pembrolizumab in HNSCC.

Postprogression access to effective therapy was linked to smaller OS benefits in targeted therapy trials but not immunotherapy trials, an analysis found.

The complete response letter did not cite any clinical issues regarding the NDA for 177Lu-edotreotide for GEP-NETs.

Nationwide data show CGP turnaround improves, but biopsy-to-order delays vary widely, slowing biomarker-driven care in lung and solid tumors.

During a live event, Sikander Ailawadhi, MD, and participants discussed how the route of CD38-antibody delivery, including a newly approved on-body injector, is shaping frontline regimen selection for transplant-ineligible multiple myeloma.

Ravi Salgia, MD, PhD, explains the goals of IMMUNO-BIOMAP, a phase 2 trial identifying biomarkers to predict immunotherapy response in NSCLC.

The FDA's Molecular and Clinical Genetics Panel will meet Sept. 23, 2026, to evaluate GRAIL's premarket approval application for the Galleri MCED test.

Liso-cel CAR T plus ibrutinib delivers deep remissions and high uMRD in relapsed CLL/SLL after multiple therapies, with manageable safety.

Benjamin Herzberg, MD, discusses unmet needs, immunotherapy sequencing, and referral timing in KRAS-mutant NSCLC.

A multimodal deep learning model trained in the NSABP B-42 trial and validated in TAILORx predicted late distant recurrence risk in HR-positive breast cancer.

Neoadjuvant inetetamab plus pyrotinib and chemotherapy achieved a 60.2% total pathologic complete response rate in the phase 2 neoPICD trial.

NMDP research showed several states and regions at risk of limited access to hematopoietic cell transplantation that can save the lives of patients with cancer.

South Korean cohort shows heavy drinking sharply raises liver cancer risk after 60, guiding age-tailored screening and prevention.

The tumor-infiltrating lymphocyte therapy has demonstrated potential for more convenient tissue collection and administration, an unmet need in advanced melanoma.

The FDA approved vusolimogene oderparepvec-wtpg plus nivolumab for PD-1–refractory advanced melanoma after a 10-3 advisory vote in favor of the oncolytic therapy.

Bria-PROS+, an off-the-shelf, whole-cell immunotherapy, will advance into clinical trials in prostate cancer after the IND was cleared.

Explore how REMS removal streamlines CAR T access in second-line DLBCL, plus smart bridging options and who qualifies when relapse strikes fast.

Five-year SENOMAC trial results show omitting completion axillary dissection preserves survival and significantly reduces arm morbidity, says Jana de Boniface, MD, PhD.

Large Ontario cohort study finds lifetime breast and ovarian cancer risk varies sharply by BRCA1/BRCA2 test result, including in those with inconclusive or negative findings.

Experts weigh TiNivo-2 and CONTACT-03, urging caution on PD-1 rechallenge in RCC and guiding tivozanib vs cabozantinib choices.

Neoadjuvant leukocyte interleukin injection demonstrated efficacy in a biomarker-selected population, supporting a planned phase 3 trial in the locally advanced resectable oral cancer setting.

FDA grants orphan status to DLL3-targeting ADC zocilurtatug pelitecan, boosting hopes for new options in hard-to-treat neuroendocrine cancers.